Antibiotic delivery polyurethanes containing albumin and polyallylamine nanoparticles

Crisante, Fernanda; Francolini, Iolanda; Bellusci, Mariangela; Martinelli, Andrea; D’Ilario, L.; Piozzi, Antonella

doi:10.1016/j.ejps.2008.12.006

Cited by 77 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…107 These pore forming delivery carriers can be useful, especially against mesh-related infection. 108 As an example, coating meshes with an ofloxacincontaining poly(ε-caprolactone) demonstrated prolonged and persistent release (72 hours), against E. Coli, S. aureus, S. epidermis, 109 Enterobacteriaceae, and some Gram-positive cocci that constitute nosocomial pathogens. 110,111 Efficacy can be improved further by drug combinations to increase the antibacterial spectrum of the anti-infective mesh and reduce the risk of selecting resistant bacteria.…”

Section: Polymer Drug Carriermentioning

confidence: 99%

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Kasimanickam¹,

Ranjan²,

Asokan³

et al. 2013

IJN

View full text Add to dashboard Cite

Bacteria growing as adherent biofilms are difficult to treat and frequently develop resistance to antimicrobial agents. To counter biofilms, various approaches, including prevention of bacterial surface adherence, application of device applicators, and assimilation of antimicrobials in targeted drug delivery machinery, have been utilized. These methods are also combined to achieve synergistic bacterial killing. This review discusses various multimodal technologies, presents general concepts, and describes therapies relying on the principles of electrical energy, ultrasound, photodynamics, and targeted drug delivery for prevention and treatment of biofilms.

show abstract

Section: Polymer Drug Carriermentioning

confidence: 99%

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Kasimanickam¹,

Ranjan²,

Asokan³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…Abraxane™ is the first US Food and Drug Administration (FDA)-approved chemotherapeutic formulation based on nanotechnology. 20 To date, the main preparation methods of albumin-based formations can be concluded into four techniques: emulsification, 21 thermal gelation, 22 desolvation (coacervation), 23 and nab™. 24 While the first three conventional techniques involve chemical cross-linking processes or heat denaturation, nab™ oxidizes sulfhydryl residues in albumin through homogenization to form new cross-linking disulfide bonds, without denaturing albumin.…”

Section: Introductionmentioning

confidence: 99%

A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy

Yin

Dong

Cui

et al. 2015

IJN

View full text Add to dashboard Cite

Clinically, paclitaxel (PTX) is one of most commonly prescribed therapies against a wide range of solid neoplasms. Despite its success, the clinical applicability of PTX (Taxol ® ) is severely hampered by systemic toxicities induced by Cremophor EL. While attempts to bypass the need for Cremophor EL have been developed through platforms such as Abraxane™, nab™ relies heavily on the use of organic solvents, namely, chloroform. The toxicity introduced by residual chloroform poses a potential risk to patient health. To mitigate the toxicities of toxic organic solvent-based manufacture methods, we have designed a method for the formulation of PTX nanosuspensions (PTX-PEG [polyethylene glycol]-HSA [human serum albumin]) that eliminates the dependence on toxic organic solvents. Coined the solid-dispersion technology, this technique permits the dispersion of PTX into PEG skeleton without the use of organic solvents or Cremophor EL as a solubilizer. Once the PTX-PEG dispersion is complete, the dispersion can be formulated with HSA into nanosuspensions suitable for intravenous administration. Additionally, the incorporation of PEG permits the prolonged circulation through the steric stabilization effect. Finally, HSA-mediated targeting permits active receptor-mediated endocytosis for enhanced tumor uptake and reduced side effects. By eliminating the need for both Cremophor EL and organic solvents while simultaneously increasing antitumor efficacy, this method provides a superior alternative to currently accepted methods for PTX delivery.

show abstract

“…TPUs as drug delivery matrices have been widely studied. They have proven versatility for the delivery of therapeutics such as antimicrobial agents (Crisante, Francolini et al 2009), anticancer drugs (Chen, Wang et al 2011) and anti-inflammatory drugs (Da Silva, Ayres et al 2009). TPUs can be synthesized from a variety of chemical building blocks, which enables structural flexibility for a range of biological applications.…”

Section: Discussionmentioning

confidence: 99%

“…Polyurethane matrices incorporating drugs have been investigated in different areas, such as cancer therapy (Yu, Ding et al 2014), tissue regeneration (Liu, Zhang et al 2010), treatment of infections (Crisante, Francolini et al 2009), and anti-inflammatory therapies (Moura, Lima et al 2011). …”

Section: Polyurethanes As Drug Delivery Matricesmentioning

confidence: 99%

See 1 more Smart Citation

Delivery of therapeutic peptides from thermoplastic polyurethane films

Zhang¹

View full text Add to dashboard Cite

Thermoplastic polyurethanes (TPUs) are widely used in biomedical applications due to their excellent mechanical properties and biocompatibility. Their roles as matrices to incorporate therapeutics have been investigated in different areas. With the advance of peptides as therapeutics, there is critical need for investigating delivery of peptides using drug delivery systems. However, there is little work on understanding the release of peptides from TPUs. The aim of this study is to understand how therapeutic peptides might be incorporated and released from TPUs.Initially, we compared the effect of supercritical carbon dioxide treatment and solvent casting on the loading and release of model drugs from polyurethane films. We found that scCO2 treatment may cause a shift of hard segment to the surface of film, but this treatment did not significantly affect physical properties of TPUs. This rearrangement of hard segment caused by scCO2 may affect drug release. We then examined the loading and release of 3 model drugs using scCO2 and compared with solvent casting. ScCO2 was able to load all these 3 model drugs consistently and homogeneously into the films, and the release of these 3 drugs was qualitatively similar by scCO2 or solvent casting.However, the amount of drug accumulated in the films by scCO2 was much less than the total amount of drug in the reaction vessel. This could be a practical limitation for therapeutics such as peptides that are expensive to synthesise. In addition, we found the composition of hard and soft segments may contribute greatly to the efflux of drugs.On the basis of these results, we next investigated the in vitro efflux of peptides from polyurethane films by solvent casting. Interestingly, we found there was a correlation between cumulative release and molecular weight of the peptides. Because one of the causes of implant failure is localised inflammation, we were specifically interested in the delivery of C5aR antagonists from TPU films. First, we found that cyclic peptides may be more stable under harsh casting conditions (elevated temperatures, organic solvents) compared to the linear peptides. Mild conditions are required to retain the bioactivity of peptides. Interestingly, similar to the efflux results of model drugs, the release profiles of peptides were also dependent on the composition of hard and soft segments of TPUs. We also found serum proteins in the medium could facilitate the release of peptides. In addition, in vitro bioactivity of the released peptides was examined by measuring intercellular Ca 2+ concentration mobilization in a cell model of C5a receptor signaling. The ii results demonstrate that released peptides retained their bioactivity. To better control the efflux of peptides, we examined blending of different TPUs. We found that the initial rate and extent of drug released from Tecoflex 80A was significant suppressed by increasing the amount of ElastEon 5325 in the blend. These results offer a simple approach for controlling drug release from TPUs.Furt...

show abstract

Antibiotic delivery polyurethanes containing albumin and polyallylamine nanoparticles

Cited by 77 publications

References 31 publications

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Prevention and treatment of biofilms by hybrid- and nanotechnologies

A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy

Delivery of therapeutic peptides from thermoplastic polyurethane films

Contact Info

Product

Resources

About

Antibiotic delivery polyurethanes containing albumin and polyallylamine nanoparticles

Cited by 77 publications

References 31 publications

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Prevention and treatment of biofilms by hybrid- and nanotechnologies

A toxic organic solvent-free technology&nbsp;for&nbsp;the preparation of PEGylated paclitaxel&nbsp;nanosuspension based on human serum albumin for effective cancer therapy

Delivery of therapeutic peptides from thermoplastic polyurethane films

Contact Info

Product

Resources

About

A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy